WorldHeart Will Learn Fate Of Novacor As Destination Therapy Within 90 Days
This article was originally published in The Gray Sheet
Executive Summary
WorldHeart may ask FDA's Medical Device Dispute Resolution Panel to re-evaluate the firm's PMA supplement for the Novacor left-ventricular assist device as a destination therapy, according to CEO Rod Bryden
You may also be interested in...
WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
WorldHeart likely will abandon efforts to earn FDA supplemental approval for the Novacor left-ventricular assist device as destination therapy based on results from the INTrEPID trial
WorldHeart Changes LVAD Development Plan, Cites Medicare Trial Coverage
WorldHeart likely will abandon efforts to earn FDA supplemental approval for the Novacor left-ventricular assist device as destination therapy based on results from the INTrEPID trial
Thoratec HeartMate Receives Long-Awaited Destination Therapy Indication
Thoratec will target major transplant and open-heart surgery centers in a new marketing initiative to promote the HeartMate SNAP-VE left ventricular assist device as a destination, "alternative-to-transplant" therapy for end-stage heart failure. FDA approved a PMA supplement for the indication on Nov. 6